Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FTY720 Extension Study in Renal Transplant
NCT00239902Phase 2Completed
- Sponsor
- Novartis
- Start
- May 2002
- Primary completion
- Nov 2004
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, single-blind trial of fingolimod in kidney transplant rejection (2 arms), sponsored by Novartis. Primary endpoints: Biopsy Proven Acute Rejection, Permanent Resumption of Dialysis and 3 more. Started May 2002; status: completed.
02
Drugs
fingolimod
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT00239902.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00239902.